BACKGROUND: Our goal was to perform an extensive systematic review of the literature on the use of electroconvulsive therapy (ECT) for @entity159 ( @entity159 ). METHODS: Articles from MEDLINE, BIOSIS, EMBASE, Healthstar, Global Health, Scopus, Cochrane Library, the International Clinical Trials Registry Platform, clinicaltrials.gov (inception to August 2015), reference lists of relevant articles, and gray literature were searched. The strength of evidence was adjudicated using both the Oxford and GRADE methodology by two independent reviewers. RESULTS: We identified 14 original articles with a total of 19 @entity1 receiving ECT for @entity159 . Of the 19 @entity1 , 15 were adult, and 4 were pediatric. All studies were retrospective in nature. @entity410 reduction/control with the application of ECT occurred in 11 of the 19 @entity1 (57.9%), with 4 (21.0%) and 7 (36.8%) displaying partial and complete responses respectively. @entity410 control lasted for variable duration, with the most commonly quoted duration ranging from 2 weeks to 3 months. Data on @entity1 functional outcome was available in 13 @entity1 , with 10 @entity1 falling into the categories of dead or severely disabled. All studies were an Oxford level 4, GRADE D level of evidence. CONCLUSIONS: Oxford level 4, GRADE D evidence exists to suggest an improvement in @entity410 control with ECT application for @entity159 . Routine use of ECT cannot be recommended at this time. Further prospective study of this therapy is required in order to determine its efficacy in this setting.

Electroconvulsive therapy for XXXX : A systematic review.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'Seizures', 'Seizure'] @entity159 :: ('MESH:D013226', 'Disease') :: ['refractory status epilepticus', 'RSE']
@entity159 :: (MESH:D013226,Disease) :: ['refractory status epilepticus']
